Resumen de Perspectiva emocional del uso de la tecnología
- español
El uso de la tecnología en diabetes mellitus (DM) generalmente conduce a resultados favorables en términos de reducción del distrés relacionado a la DM reportado por los pacientes, mejoría en la satisfacción con el tratamiento o reducción de la depresión. Esto es así para el uso de bombas de infusión de insulina, sensores continuos de glucemia, así como para los sistemas automatizados de infusión de insulina denominados “páncreas artificial”, aunque la evidencia para este último es escasa.
Independientemente del tipo de tecnología, un hallazgo clínico intrigante y relevante es la variabilidad interindividual con respecto al uso de la tecnología. No todos los individuos usan bomba o sensor continuo constantemente (en términos del tiempo en que los aparatos deberían usarse) y, por lo tanto, no pueden beneficiarse de ellos en toda su extensión. Aún debe investigarse por qué algunos individuos no se “enganchan” con el uso de la tecnología en DM o la abandonan. Además, los profesionales de la salud necesitan proveer educación sobre la tecnología; sin embargo, no todos están capacitados para conversar con los pacientes acerca de las bombas/sensores continuos de glucosa/páncreas artificial y el sistema de datos.
- English
Diabetes technology generally yields favourable results in terms of self-reported outcomes such as reduced diabetes distress, improved treatment satisfaction or reduced depression. This holds true for CSII and CGM, as well as for automated insulin delivery systems, albeit evidence for thelatter is still limited.Irrespective of the type of thecnology, a most intriguing and clinically relevant finding pertains to interindividual variability in diabetes thecnology uptake.Not all individuals use CSII or CGM consequentially (in terms of time the devices are used) and, therefore, cannot benefit from CSII or CGM to the full extent. It remains to be fully clarified as to why some individuals do not engage with diabetes technologies or even discontinue their use altogether, Furthermore, healthcareprofessionals need to be able to provide education about technologies; however, not all are able to discuss CGM/pump/automated insulin delivery system data. Psychosocial barriersA recent large-scale survey in people with type 1 diabetes examined barriers in diabetes technology uptake covering CSII and CGM. Two barriers that were indentified stood out. Almost half of the respondents referred to the hassle of wearing the device as a significant barrier, and disliking device on one's body was mentioned by approximately one-third of the respondents. Constantly wearing a diabetes device on one's body may negatively impact body image in select individuals.Vloemans et al also highlight that some CGM users experience feelings of frustation due to frequentalarms, information overload and technical defects that may dampen their trust in the technology. Borges Jr and Kubiak also showed that fears (such as being dependent on a technical device) or unrealistic expectations (such as being 100% safe when it comes to hypoglycemia) may hamper diabetes technology uptake.ConclusionsDiabetes technology continues to have an increasing impact in diabetes self-management and care.Research is very much needed in the área of barriers and facilitating conditions of diabetes technology uptake and success.
